CClinicalTrials.gg
CompletedNCT04730297Updated Jan 29, 2021

Comparative Analgesic Effects of Paracetamol/Codeine and Ibuprofen on Pain After Third Molar Surgery

A Phase 4 interventional study of paracetamol 500 mg plus codeine 30 mg preoperative administration and ibuprofen 400 mg preoperative administration in To Control Pain After Third Molar Surgery, sponsored by University of Roma La Sapienza. Completed at 1 site in Italy. Open to participants aged 15 Years to 29 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-01-29.

Sponsored by University of Roma La Sapienza · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 3 years after the study started (first participant enrolled Jan 2018, registered Jan 2021).
Phase
Phase 4
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
15 Years to 29 Years
Sex
All
01

Study summary

To compare analgesic effects of preoperative administration of paracetamol 500 milligram plus codeine 30 milligram in single-tablet and effervescent formulation to ibuprofen 400 milligram, and placebo in the management of moderate to severe postoperative pain after mandibular third molar surgery.

Read the detailed description

Materials and methods: One hundred twenty healthy outpatients aged 15 to 29 years undergoing surgical removal of one bony impacted mandibular third molar were enrolled in this, single-center, prospective, randomized, triple-blind parallel-group, placebo-controlled, clinical trial. Study participants were randomly assigned to three treatment arms. According to the concealed allocation, each patient 30 minutes before surgery received paracetamol 500 mg plus codeine 30 mg (group A), ibuprofen 400 mg (group B) or placebo (group C). Rescue therapy allowed in the postoperative period was paracetamol 500 mg plus codeine 30 mg in groups A and C and ibuprofen 400 mg in group B. Patients recorded on Numerical Rating Scale-11 (NRS-11) the pain intensity, total number of postoperative-supplement medications and time of the first intake, until 12-hours after surgery and over extra two days

02

Conditions studied

  • To Control Pain After Third Molar Surgery

Keywords

  • postsurgical dental pain
03

In context

Lead sponsor

University of Roma La Sapienza is the lead sponsor of 388 studies on the registry; 55 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
15 Years to 29 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • healthy status (ASA class I);
  • nonsmoker;
  • not pregnant or breastfeeding;
  • no medication consumption in the past 21 days;
  • good oral hygiene;
  • bony impaction of one mandibular third molars;
  • the presence of the first and second molars;
  • compliance to cooperate with the research protocol.

Exclusion criteria

Exclusion Criteria:

  • chronic systemic disease;
  • medications with potential interaction to paracetamol-codeine or ibuprofen;
  • a history of intolerance or hypersensitivity to the study drugs;
  • any pre-existing pain and acute inflammatory or infectious conditions; - inability to understand or perform the study procedure.
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
120 participants (actual)

Study arms

  • Active comparator
    Paracetamol/codeine Group A

    analgesic group preoperative oral dose of paracetamol 500 mg plus codeine 30 mg

    Drug: paracetamol 500 mg plus codeine 30 mg preoperative administration

  • Active comparator
    Ibuprofen Group B

    analgesic group preoperative oral dose of ibuprofen 400 mg

    Drug: ibuprofen 400 mg preoperative administration

  • Placebo comparator
    Placebo Group C

    Placebo group preoperative placebo

    Drug: Placebo oral tablet preoperative administration

Interventions

  • Drugparacetamol 500 mg plus codeine 30 mg preoperative administration

    each patient 30 minutes before surgery received paracetamol 500 mg plus codeine 30 mg

    Also known as: GROUP A

  • Drugibuprofen 400 mg preoperative administration

    each patient 30 minutes before surgery received ibuprofen 400 mg

    Also known as: GROUP B

  • DrugPlacebo oral tablet preoperative administration

    each patient 30 minutes before surgery received placebo

    Also known as: GROUP C

06

What researchers measure

Primary outcomes

  1. Pain measurement assessed with the Numerical Rating Scale-11 (NRS-11)

    In stage 1, the objective was to misure the efficacy on pain and tolerability of a single dose of paracetamol plus codeine, ibuprofen, or placebo in the operative day. Before surgery, patients were instructed to complete the Numerical Rating Scale-11 (NRS-11), which consisted of an interval scale ranging from 0 ("no pain") to 10 ("maximum pain")

    Time frame: All study participants were asked to record the pain intensity score at 1:00 pm during the operative day]

  2. Pain measurement assessed with the Numerical Rating Scale-11 (NRS-11)

    In stage 1, the objective was to compare the efficacy on pain and tolerability of a single dose of paracetamol plus codeine, ibuprofen, or placebo in the operative day.

    Time frame: All study participants were asked to record the pain intensity score at 6:00 pm during the operative day]

  3. Pain measurement assessed with the Numerical Rating Scale-11 (NRS-11)

    In stage 1, the objective was to compare the efficacy on pain and tolerability of a single dose of paracetamol plus codeine, ibuprofen, or placebo in the operative day.

    Time frame: All study participants were asked to record the pain intensity score at 11:00 pm during the operative day]

  4. Pain measurement assessed with the Numerical Rating Scale-11 (NRS-11)

    In stage 1, the objective was to compare the efficacy on pain and tolerability of a single dose of paracetamol plus codeine, ibuprofen, or placebo

    Time frame: All study participants were asked to record the pain intensity score at 8:00 am during the 2th day after surgery]

  5. Pain measurement assessed with the Numerical Rating Scale-11 (NRS-11)

    In stage 1, the objective was to compare the efficacy on pain and tolerability of a single dose of paracetamol plus codeine, ibuprofen, or placebo

    Time frame: All study participants were asked to record the pain intensity score at 1:00 pm during the 2th day after surgery]

  6. Pain measurement assessed with the Numerical Rating Scale-11 (NRS-11)

    In stage 1, the objective was to compare the efficacy on pain and tolerability of a single dose of paracetamol plus codeine, ibuprofen, or placebo

    Time frame: All study participants were asked to record the pain intensity score at 6:00 pm during the 2th day after surgery]

  7. Pain measurement assessed with the Numerical Rating Scale-11 (NRS-11)

    In stage 1, the objective was to compare the efficacy on pain and tolerability of a single dose of paracetamol plus codeine, ibuprofen, or placebo in the operative day.

    Time frame: All study participants were asked to record the pain intensity score at 11:00 pm during the 2th day after surgery]

  8. Pain measurement assessed with the Numerical Rating Scale-11 (NRS-11)

    In stage 1, the objective was to compare the efficacy on pain and tolerability of a single dose of paracetamol plus codeine, ibuprofen, or placebo in the operative day.

    Time frame: All study participants were asked to record the pain intensity score at 8:00 am during the 3th day after surgery]

  9. Pain measurement assessed with the Numerical Rating Scale-11 (NRS-11)

    In stage 1, the objective was to compare the efficacy on pain and tolerability of a single dose of paracetamol plus codeine, ibuprofen, or placebo in the operative day.

    Time frame: All study participants were asked to record the pain intensity score at 1:00 pm during the 3th day after surgery]

  10. Pain measurement assessed with the Numerical Rating Scale-11 (NRS-11)

    In stage 1, the objective was to compare the efficacy on pain and tolerability of a single dose of paracetamol plus codeine, ibuprofen, or placebo in the operative day.

    Time frame: All study participants were asked to record the pain intensity score at 6:00 pm during the 3th day after surgery]

  11. Pain measurement assessed with the Numerical Rating Scale-11 (NRS-11)

    In stage 1, the objective was to compare the efficacy on pain and tolerability of a single dose of paracetamol plus codeine, ibuprofen, or placebo in the operative day.

    Time frame: All study participants were asked to record the pain intensity score at 11:00 pm during the 3th day after surgery]

Secondary outcomes

  1. Number of patients requiring rescue therapy

    outcomes involved the number of patients requiring rescue therapy

    Time frame: until 12-hours after surgery and over extra two days

  2. first postoperative use of analgesics

    time of the first intake

    Time frame: until 12-hours after surgery

  3. total postoperative use of analgesics

    total amount of additional medication

    Time frame: until 12-hours after surgery and over extra two days

Other outcomes

  1. Compare the efficacy of the same drugs

    Patients recorded on Numerical Rating Scale-11 (NRS-11) the pain intensity

    Time frame: up to 48 hours after stage 1

07

Study locations

1 site
  • Maria Paola Cristalli
    Roma, 00100, Italy
08

References and documents

Publications

  • La Monaca G, Pranno N, Annibali S, Polimeni A, Pompa G, Vozza I, Cristalli MP. COMPARATIVE ANALGESIC EFFECTS OF SINGLE-DOSE PREOPERATIVE ADMINISTRATION OF PARACETAMOL (ACETAMINOPHEN) 500 mg PLUS CODEINE 30 mg AND IBUPROFEN 400 mg ON PAIN AFTER THIRD MOLAR SURGERY. J Evid Based Dent Pract. 2021 Dec;21(4):101611. doi: 10.1016/j.jebdp.2021.101611. Epub 2021 Jul 10. PubMed 34922726 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 29, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04730297
Lead sponsor
University of Roma La Sapienza
Responsible party
Maria Paola Cristalli (Associate Professor DDS, PhD, University of Roma La Sapienza) — Principal investigator
First posted
Jan 29, 2021
Start date
Jan 1, 2018
Primary completion
Sep 4, 2020
Completion
Oct 14, 2020
Last update
Jan 29, 2021

Study contacts

Maria Paola Cristalli, DDS, PhD
principal investigator · University of Roma La Sapienza

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion